Report of Foreign Issuer (6-k)
August 29 2019 - 8:29AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
August 2019
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On August 29, 2019,
Akari Therapeutics, Plc (the “Company”) issued unaudited interim condensed consolidated financial statements as of
June 30, 2019, prepared in accordance with generally accepted accounting principles in the United States, together with the Company’s
Management Discussion and Analysis of Financial Condition and Results of Operations for the same period. Attached hereto and incorporated
by reference herein are the following exhibits:
99.1
|
Unaudited Interim Condensed Consolidated Financial
Statements as of June 30, 2019
|
99.2
|
Management Discussion and Analysis of Financial
Condition and Results of Operations as of June 30, 2019
|
In addition, on August
29, 2019, the Company issued a press release announcing its second quarter 2019 financial results and recent clinical progress
highlights. A copy of the press release is attached hereto as Exhibit 99.3 and incorporated herein by reference.
The information contained
in Exhibits 99.1 and 99.2 and the statements under “Second Quarter 2019 Financial Results”, the accompanying financial
statements and “Cautionary Note Regarding Forward-Looking Statements” of Exhibit 99.3 are hereby incorporated by reference
into all effective registration statements filed by the Company under the Securities Act of 1933.
Exhibit No.
99.1
|
Unaudited Interim Condensed Consolidated Financial Statements
as of June 30, 2019
|
|
|
99.2
|
Management Discussion and Analysis of Financial Condition and
Results of Operations as of June 30, 2019
|
|
|
99.3
|
Press release dated August 29, 2019
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Akari Therapeutics, Plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
By:
|
/s/ Clive Richardson
|
|
|
Name:
|
Clive Richardson
|
|
|
|
Chief Executive Officer and Chief Operating Officer
|
|
Date: August 29, 2019
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024